{"pmid":32448761,"title":"Endocrine surgery during and after the COVID-19 epidemic: Expert guidelines from AFCE.","text":["Endocrine surgery during and after the COVID-19 epidemic: Expert guidelines from AFCE.","The COVID-19 pandemic commands a major reorganisation of the entire French healthcare system. In France, general rules have been issued nationally and implemented by each healthcare centre, both public and private, throughout France. Guidelines drafted by an expert group led by the French-speaking Association of Endocrine Surgery (AFCE) propose specific surgical management principles for thyroid, parathyroid, endocrine pancreas and adrenal surgery during and after the COVID-19 epidemic.","J Visc Surg","Baud, G","Brunaud, L","Lifante, J-C","Tresallet, C","Sebag, F","Bizard, J-P","Mathonnet, M","Menegaux, F","Caiazzo, R","Mirallie, E","Pattou, F","32448761"],"abstract":["The COVID-19 pandemic commands a major reorganisation of the entire French healthcare system. In France, general rules have been issued nationally and implemented by each healthcare centre, both public and private, throughout France. Guidelines drafted by an expert group led by the French-speaking Association of Endocrine Surgery (AFCE) propose specific surgical management principles for thyroid, parathyroid, endocrine pancreas and adrenal surgery during and after the COVID-19 epidemic."],"journal":"J Visc Surg","authors":["Baud, G","Brunaud, L","Lifante, J-C","Tresallet, C","Sebag, F","Bizard, J-P","Mathonnet, M","Menegaux, F","Caiazzo, R","Mirallie, E","Pattou, F"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448761","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jviscsurg.2020.04.018","keywords":["adrenal","covid-19","coronavirus","endocrine surgery","neuroendocrine tumour","parathyroid","thyroid"],"locations":["French","France","France","French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention"],"weight":1,"_version_":1667785213906780161,"score":9.490897,"similar":[{"pmid":32355510,"pmcid":"PMC7190492","title":"[Endocrine surgery during and after the COVID-19 epidemic: guidelines from AFCE].","text":["[Endocrine surgery during and after the COVID-19 epidemic: guidelines from AFCE].","The Covid-19 pandemic commands a major reorganization of the entire French healthcare system. In France, general rules have been issued nationally and implemented by each healthcare center, both public and private, throughout France. Guidelines drafted by an expert group led by the French-speaking Association of Endocrine Surgery (AFCE) propose specific surgical management principles for thyroid, parathyroid, endocrine pancreas and adrenal surgery during and after the Covid-19 epidemic.","Baud, Gregory","Brunaud, Laurent","Lifante, Jean Christophe","Tresallet, Christophe","Sebag, Frederic","Bizard, Jean Pierre","Mathonnet, Muriel","Menegaux, Fabrice","Caiazzo, Robert","Mirallie, Eric","Pattou, Francois","32355510"],"abstract":["The Covid-19 pandemic commands a major reorganization of the entire French healthcare system. In France, general rules have been issued nationally and implemented by each healthcare center, both public and private, throughout France. Guidelines drafted by an expert group led by the French-speaking Association of Endocrine Surgery (AFCE) propose specific surgical management principles for thyroid, parathyroid, endocrine pancreas and adrenal surgery during and after the Covid-19 epidemic."],"authors":["Baud, Gregory","Brunaud, Laurent","Lifante, Jean Christophe","Tresallet, Christophe","Sebag, Frederic","Bizard, Jean Pierre","Mathonnet, Muriel","Menegaux, Fabrice","Caiazzo, Robert","Mirallie, Eric","Pattou, Francois"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32355510","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jchirv.2020.04.015","locations":["French","France","France","French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Prevention"],"weight":1,"_version_":1666138495209439233,"score":906.50323},{"pmid":32500518,"pmcid":"PMC7270156","title":"Endocrine surgery during COVID-19 pandemic: do we need an update of indications in Italy?","text":["Endocrine surgery during COVID-19 pandemic: do we need an update of indications in Italy?","The ongoing spread of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a significant threat to global health. As the coronavirus outbreak began spreading, hospitals were forced to relocate resources to treat the growing number of COVID-19 patients. As a consequence, doctors across the country canceled tens of thousands of nonurgent surgeries. However, recognizing that the COVID-19 situation may be highly variable and fluid in different communities across the country, elective surgery could be still allowed in some centers for patients included in the high-priority class. The majority of endocrine disorders requiring surgical treatment in patients identifiable as first-priority class, or needing hospitalization within 30 days, are generally represented by malignant thyroid tumors, hyperthyroidism, hyperparathyroidism, and some adrenal disorders. The need for urgent intervention is evaluated on a case-by-case basis according to the severity of the symptoms, the likelihood of progression, and global clinical judgment. On the basis of the above indications, during the last 4 weeks, we performed 18 planned surgical treatments in patients with thyroid cancer (total thyroidectomies, plus lymph node dissection if needed) or multinodular toxic goiter. In no case, postoperative ventilatory support was needed, and the average hospital stay was 3 days. The negative COVID-19 status for all the treated patients was appropriately evaluated beforehand. Nobody knows how long the current COVID-19 pandemic will be lasting. Certainly, we will be requested in the next future to incrementally offer surgical services for endocrine disorders that have been deferred for the COVID-19 pandemic.","Endocrine","Lombardi, Celestino Pio","D'Amore, Annamaria","Grani, Giorgio","Ramundo, Valeria","Boscherini, Mauro","Gordini, Luca","Marzi, Federica","Tedesco, Silvia","Bocale, Raffaella","32500518"],"abstract":["The ongoing spread of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a significant threat to global health. As the coronavirus outbreak began spreading, hospitals were forced to relocate resources to treat the growing number of COVID-19 patients. As a consequence, doctors across the country canceled tens of thousands of nonurgent surgeries. However, recognizing that the COVID-19 situation may be highly variable and fluid in different communities across the country, elective surgery could be still allowed in some centers for patients included in the high-priority class. The majority of endocrine disorders requiring surgical treatment in patients identifiable as first-priority class, or needing hospitalization within 30 days, are generally represented by malignant thyroid tumors, hyperthyroidism, hyperparathyroidism, and some adrenal disorders. The need for urgent intervention is evaluated on a case-by-case basis according to the severity of the symptoms, the likelihood of progression, and global clinical judgment. On the basis of the above indications, during the last 4 weeks, we performed 18 planned surgical treatments in patients with thyroid cancer (total thyroidectomies, plus lymph node dissection if needed) or multinodular toxic goiter. In no case, postoperative ventilatory support was needed, and the average hospital stay was 3 days. The negative COVID-19 status for all the treated patients was appropriately evaluated beforehand. Nobody knows how long the current COVID-19 pandemic will be lasting. Certainly, we will be requested in the next future to incrementally offer surgical services for endocrine disorders that have been deferred for the COVID-19 pandemic."],"journal":"Endocrine","authors":["Lombardi, Celestino Pio","D'Amore, Annamaria","Grani, Giorgio","Ramundo, Valeria","Boscherini, Mauro","Gordini, Luca","Marzi, Federica","Tedesco, Silvia","Bocale, Raffaella"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500518","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s12020-020-02357-7","keywords":["covid-19","endocrine emergencies","endocrine surgery","thyroid cancer"],"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1668890966443950080,"score":276.12543},{"pmid":32437031,"title":"Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines.","text":["Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines.","BACKGROUND: In the face of the COVID-19 pandemic, cancer care has had to adapt rapidly given the Centers for Disease Control and Prevention and the American College of Surgeons (ACS) issuing recommendations to postpone nonurgent surgeries. METHODS: An institutional multidisciplinary group of Head and Neck Surgical Oncology, Surgical Endocrinology, and Medical Endocrinology devised Surgical Triaging Guidelines for Endocrine Surgery during COVID-19, aligned with phases of care published by the ACS. RESULTS: Phases of care with examples of corresponding endocrine cases are outlined. Most cases can be safely postponed with active surveillance, including most differentiated and medullary thyroid cancers. During the most acute phase, all endocrine surgeries are deferred, except thyroid tumors requiring acute airway management. CONCLUSIONS: These guidelines provide context for endocrine surgery within the spectrum of surgical oncology, with the goal of optimal individualized multidisciplinary patient care and the expectation of significant resource diversion to care for patients with COVID-19.","Head Neck","Jozaghi, Yelda","Zafereo, Mark E","Perrier, Nancy D","Wang, Jennifer R","Grubbs, Elizabeth","Gross, Neil D","Fisher, Sarah","Sturgis, Erich M","Goepfert, Ryan P","Lai, Stephen Y","Best, Conor","Busaidy, Naifa L","Cabanillas, Maria E","Dadu, Ramona","Gagel, Robert F","Habra, Mouhammed A","Hu, Mimi I","Jimenez, Camilo","Sherman, Steven I","Thosani, Sonali","Varghese, Jeena","Waguespack, Steven G","Weitzman, Steven","Ying, Anita K","Graham, Paul H","32437031"],"abstract":["BACKGROUND: In the face of the COVID-19 pandemic, cancer care has had to adapt rapidly given the Centers for Disease Control and Prevention and the American College of Surgeons (ACS) issuing recommendations to postpone nonurgent surgeries. METHODS: An institutional multidisciplinary group of Head and Neck Surgical Oncology, Surgical Endocrinology, and Medical Endocrinology devised Surgical Triaging Guidelines for Endocrine Surgery during COVID-19, aligned with phases of care published by the ACS. RESULTS: Phases of care with examples of corresponding endocrine cases are outlined. Most cases can be safely postponed with active surveillance, including most differentiated and medullary thyroid cancers. During the most acute phase, all endocrine surgeries are deferred, except thyroid tumors requiring acute airway management. CONCLUSIONS: These guidelines provide context for endocrine surgery within the spectrum of surgical oncology, with the goal of optimal individualized multidisciplinary patient care and the expectation of significant resource diversion to care for patients with COVID-19."],"journal":"Head Neck","authors":["Jozaghi, Yelda","Zafereo, Mark E","Perrier, Nancy D","Wang, Jennifer R","Grubbs, Elizabeth","Gross, Neil D","Fisher, Sarah","Sturgis, Erich M","Goepfert, Ryan P","Lai, Stephen Y","Best, Conor","Busaidy, Naifa L","Cabanillas, Maria E","Dadu, Ramona","Gagel, Robert F","Habra, Mouhammed A","Hu, Mimi I","Jimenez, Camilo","Sherman, Steven I","Thosani, Sonali","Varghese, Jeena","Waguespack, Steven G","Weitzman, Steven","Ying, Anita K","Graham, Paul H"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437031","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/hed.26169","keywords":["covid","coronavirus","endocrine","guideline","surgery"],"locations":["optimal"],"topics":["Prevention"],"weight":1,"_version_":1667521393616486402,"score":257.24756},{"pmid":32368252,"pmcid":"PMC7192402","title":"Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic.","text":["Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic.","The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care.","Ecancermedicalscience","Marti, Covadonga","Sanchez-Mendez, Jose I","32368252"],"abstract":["The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or postponing their attendance at clinics, as well as avoiding surgeries. In this scenario, neoadjuvant endocrine treatment could be an appropriate alternative treatment for hormone receptor positive breast cancer (luminal-like tumours) in order to minimise hospital admissions and to delay elective surgeries. Accordingly, we present a simple protocol that can be applied to most cases of luminal-like breast cancer and is appropriate for the majority of secondary or tertiary medical centres, or even primary care."],"journal":"Ecancermedicalscience","authors":["Marti, Covadonga","Sanchez-Mendez, Jose I"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32368252","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.3332/ecancer.2020.1027","keywords":["covid-19","breast cancer","endocrine therapy","luminal","neoadjuvant"],"topics":["Prevention"],"weight":1,"_version_":1666138496290521088,"score":141.52217},{"pmid":32471705,"title":"[Responsiveness and sustainability of psychiatric care in France during COVID-19 epidemic].","text":["[Responsiveness and sustainability of psychiatric care in France during COVID-19 epidemic].","OBJECTIVES: The sudden changes of healthcare system due to COVID-19 particularly affect the organization of psychiatry. The objective of this review is to examine the adaptations of psychiatric care in France during this pandemic. METHOD: This narrative review is based on the observation of changes made in French psychiatric hospitals and on an analysis of the literature. RESULTS: Regarding psychiatric hospitalization, the COVID-19 epidemic required rapid measures that profoundly modified the conditions of patients' reception, forcing the medical staffs to adapt their methods of care. The authors noted the creation of at least 89 wards specifically dedicated to patients with COVID-19 needing psychiatric hospitalization, allowing dual care of general medicine and psychiatry. Regarding ambulatory care, maintaining patients with long-term follow-up was a priority. Patients recalling and teleconsultation have been precious resources but cannot entirely replace face-to-face consultations. DISCUSSION: COVID-19 epidemic created unprecedented situation of large-scale upheavals in the healthcare system and in society. Despite the absence of previous recommendations on the subject, French psychiatry has shown great adaptability. Some changes could inspire post-COVID-19 care.","Encephale","Bocher, R","Jansen, C","Gayet, P","Gorwood, P","Laprevote, V","32471705"],"abstract":["OBJECTIVES: The sudden changes of healthcare system due to COVID-19 particularly affect the organization of psychiatry. The objective of this review is to examine the adaptations of psychiatric care in France during this pandemic. METHOD: This narrative review is based on the observation of changes made in French psychiatric hospitals and on an analysis of the literature. RESULTS: Regarding psychiatric hospitalization, the COVID-19 epidemic required rapid measures that profoundly modified the conditions of patients' reception, forcing the medical staffs to adapt their methods of care. The authors noted the creation of at least 89 wards specifically dedicated to patients with COVID-19 needing psychiatric hospitalization, allowing dual care of general medicine and psychiatry. Regarding ambulatory care, maintaining patients with long-term follow-up was a priority. Patients recalling and teleconsultation have been precious resources but cannot entirely replace face-to-face consultations. DISCUSSION: COVID-19 epidemic created unprecedented situation of large-scale upheavals in the healthcare system and in society. Despite the absence of previous recommendations on the subject, French psychiatry has shown great adaptability. Some changes could inspire post-COVID-19 care."],"journal":"Encephale","authors":["Bocher, R","Jansen, C","Gayet, P","Gorwood, P","Laprevote, V"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471705","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.encep.2020.05.004","keywords":["covid-19","health system","hospitalisation","hospitalization","organisation des soins","psychiatrie","psychiatry","sars-cov-2"],"locations":["France","French","French","France"],"countries":["France"],"countries_codes":["FRA|France"],"weight":0,"_version_":1668255193318293504,"score":135.3882}]}